IPG Photonics Announces Strategic Acquisition of Lumibird Medical

On July 16, 2026, IPG Photonics Corporation (NASDAQ: IPGP), a global leader in laser technology, announced its entry into a binding offer to acquire Lumibird Medical, a move aimed at bolstering its medical laser growth platform. This strategic acquisition is set to enhance IPG's Advanced Solutions portfolio, particularly in the attractive medical markets of ophthalmology and urology.

The acquisition price for Lumibird Medical is set at €300 million on a cash-free, debt-free basis, with the transaction to be funded using cash on hand. Additionally, the agreement includes a contingent earnout consideration of up to €50 million, dependent on achieving specific performance metrics in 2026 and 2027. IPG anticipates that this acquisition will not only be accretive to its gross margin, EBITDA, and adjusted EPS, but will also significantly expand its addressable market by approximately $1 billion.

Dr. Mark Gitin, CEO of IPG Photonics, expressed optimism about the acquisition, stating, “We expect that this acquisition will accelerate our strategic expansion in attractive medical markets in Advanced Solutions.” He emphasized the complementary strengths of Lumibird Medical in ophthalmology and IPG’s established presence in urology, which will foster innovation and broaden their commercial reach.

Headquartered in France, Lumibird Medical is recognized as a global leader in diagnostic and treatment systems within the highly regulated medical laser market. The company specializes in designing and producing advanced diagnostic and therapeutic tools for a range of conditions, including cataracts, glaucoma, and age-related macular degeneration. With a robust portfolio of market-leading brands such as Quantel Medical, Ellex, and Optotek Medical, Lumibird Medical has demonstrated a consistent track record of sales growth and EBITDA margin expansion.

In its latest fiscal year ending December 31, 2025, Lumibird Medical reported revenue of €112.2 million and an impressive EBITDA of €24.1 million, reflecting an EBITDA margin of 21.5%. This solid financial performance underscores the potential value that Lumibird Medical brings to IPG Photonics.

The acquisition is expected to close in the fourth quarter of 2026, pending the completion of the information and consultation process with Lumibird Medical's works council as mandated by French law. Both companies are enthusiastic about the synergies that this merger will bring, with Jean-Marc Gendre, CEO of Lumibird Medical, asserting that joining IPG will provide significant growth opportunities while maintaining their innovative culture.

IPG Photonics will hold a conference call on July 17, 2026, at 8:00 a.m. ET to discuss the acquisition and its implications further. Stakeholders and analysts interested in gaining more insights into the transaction can participate by dialing in or accessing the live webcast, which will also be archived for later viewing.

The acquisition of Lumibird Medical marks a significant milestone for IPG Photonics as it seeks to enhance its position in the medical laser sector. By combining strengths in ophthalmology and urology, the company is well-positioned to capitalize on substantial market opportunities, foster innovation, and ultimately drive long-term value creation for shareholders. The upcoming months will be critical as IPG navigates the integration process and works towards realizing the full potential of this strategic acquisition.